“On behalf of the Neuraptive Board and its directors, we are excited to welcome Cary to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “Cary’s extensive background in the capital markets, corporate strategy, legal, and compliance make him an important addition to the Neuraptive board of directors. We are excited to have attracted such an accomplished leader in our industry as we advance our lead program toward registration and commercialization

“I am excited to join the Neuraptive Board at this time in the company’s progression , and I look forward to working with the other directors on the board and the management team,” said Cary Sucoff

Mr. Sucoff has over 35 years of legal and securities industry experience, and since 2011, he has owned and operated Equity Source Partners LLC, an advisory and consulting firm. He is an expert in legal, compliance, corporate strategy, and capital markets and has participated in the financing of hundreds of public and private companies. Mr. Sucoff is a former New York City prosecutor and currently serves on the boards of directors of ContraFect Corporation, IMAC Holdings, LLC, Curative Biotechnology, Galimedix Therapeutics, Inc., and First Wave Technologies, Inc. Mr. Sucoff earned his J.D. from New England School of Law and his B.A. from SUNY Binghamton. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.

About Neuraptive

Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Chesterbrook, PA. For more information, see www.neuraptive.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005033/en/